RU2014105172A - Способ обнаружения олигомеров бета-амилоида в образце жидкости организма и варианты его применения - Google Patents

Способ обнаружения олигомеров бета-амилоида в образце жидкости организма и варианты его применения Download PDF

Info

Publication number
RU2014105172A
RU2014105172A RU2014105172/15A RU2014105172A RU2014105172A RU 2014105172 A RU2014105172 A RU 2014105172A RU 2014105172/15 A RU2014105172/15 A RU 2014105172/15A RU 2014105172 A RU2014105172 A RU 2014105172A RU 2014105172 A RU2014105172 A RU 2014105172A
Authority
RU
Russia
Prior art keywords
ndpoi
antibody
complex
biological sample
capture antibody
Prior art date
Application number
RU2014105172/15A
Other languages
English (en)
Russian (ru)
Inventor
Мэри СЭВИДЖ
Пол ШАФРЮ
Абигейл ВУЛФ
Александр МакКЭМПБЕЛЛ
Original Assignee
Мерк Шарп И Доум Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп И Доум Корп. filed Critical Мерк Шарп И Доум Корп.
Publication of RU2014105172A publication Critical patent/RU2014105172A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
RU2014105172/15A 2011-07-13 2012-07-09 Способ обнаружения олигомеров бета-амилоида в образце жидкости организма и варианты его применения RU2014105172A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161507332P 2011-07-13 2011-07-13
US61/507,332 2011-07-13
PCT/US2012/045886 WO2013009667A1 (en) 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof

Publications (1)

Publication Number Publication Date
RU2014105172A true RU2014105172A (ru) 2015-08-20

Family

ID=47506433

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014105172/15A RU2014105172A (ru) 2011-07-13 2012-07-09 Способ обнаружения олигомеров бета-амилоида в образце жидкости организма и варианты его применения

Country Status (13)

Country Link
US (2) US20130052670A1 (cg-RX-API-DMAC10.html)
EP (2) EP2732286A4 (cg-RX-API-DMAC10.html)
JP (1) JP2014521089A (cg-RX-API-DMAC10.html)
KR (1) KR20140072019A (cg-RX-API-DMAC10.html)
CN (1) CN103782171B (cg-RX-API-DMAC10.html)
AU (1) AU2012282825B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014000671A2 (cg-RX-API-DMAC10.html)
CA (1) CA2840976A1 (cg-RX-API-DMAC10.html)
DK (1) DK2732289T3 (cg-RX-API-DMAC10.html)
ES (1) ES2666840T3 (cg-RX-API-DMAC10.html)
MX (1) MX2014000480A (cg-RX-API-DMAC10.html)
RU (1) RU2014105172A (cg-RX-API-DMAC10.html)
WO (2) WO2013009667A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220084437A (ko) 2009-06-17 2022-06-21 바이오젠 엠에이 인코포레이티드 대상에게서 smn2 스플라이싱을 조정하기 위한 조성물 및 방법
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
EP2943225A4 (en) 2013-01-09 2016-07-13 Ionis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR MODULATING SMN2 DISTRIBUTION IN THE BODY OF A PATIENT
ES2874704T3 (es) * 2013-11-20 2021-11-05 Univ Iowa Res Found Procedimiento para monitorizar la eficacia de un tratamiento de la enfermedad de Alzheimer con una isoforma de ApoE
US20170044538A1 (en) 2014-04-17 2017-02-16 Biogen Ma Inc. Compositions and Methods for Modulation of SMN2 Splicing in a Subject
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
WO2016040748A1 (en) * 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for detection of smn protein in a subject and treatment of a subject
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
JP6989927B2 (ja) * 2015-08-25 2022-02-03 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ-シヌクレインを検出するための方法
CN108603880B (zh) 2016-02-08 2021-01-05 希森美康株式会社 受试物质的检测方法及受试物质的检测用试剂盒
US11198867B2 (en) 2016-06-16 2021-12-14 Ionis Pharmaceuticals, Inc. Combinations for the modulation of SMN expression
WO2021005857A1 (ja) * 2019-07-05 2021-01-14 株式会社 島津製作所 アミロイドベータに対するモノクローナル抗体、及びその抗体を用いるアミロイドベータ関連ペプチドの測定方法
AU2021225957A1 (en) 2020-02-28 2022-09-08 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating SMN2
US20260202426A1 (en) * 2021-06-25 2026-07-16 Jae Won Chang Early diagnosis system utilizing standard deviation and autocorrelation of dynamic fluorescent or x-ray
WO2023034324A2 (en) * 2021-08-30 2023-03-09 The Brigham And Women’S Hospital, Inc. Methods and materials to treat neurodegenerative disease
EP4562427A4 (en) * 2022-07-27 2026-07-15 Durin Life Sciences Inc EARLY DETECTION AND MONITORING OF NEURODEGENERATIVE DISEASES USING A MULTI-DISEASE DIAGNOSTIC PLATFORM
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665024A (en) 1984-10-01 1987-05-12 Becton, Dickinson And Company Fluorescent gram stain
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6082205A (en) 1998-02-06 2000-07-04 Ohio State University System and device for determining particle characteristics
ATE283285T1 (de) 1999-08-04 2004-12-15 Univ Southern California Globularer aufbau vom amyloid-beta- protein und deren verwendungen
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
CA2561532A1 (en) * 2004-04-02 2005-10-20 Merck & Co., Inc. Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
KR20070094890A (ko) 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 addl 항체 및 그 용도
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
AU2006306553B9 (en) * 2005-10-21 2011-09-29 Merck Sharp & Dohme Corp. Anti-ADDL monoclonal antibody and use thereof
US20090181359A1 (en) * 2007-10-25 2009-07-16 Lou Sheng C Method of performing ultra-sensitive immunoassays
JP2013511734A (ja) * 2009-11-24 2013-04-04 プロビオドルグ エージー アルツハイマー病又は軽度認知障害の診断のための新規診断方法
US8795664B2 (en) * 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
US20130115227A1 (en) * 2010-07-14 2013-05-09 Renee C. Gaspar Anti-addl monoclonal antibody and uses thereof
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

Also Published As

Publication number Publication date
WO2013009703A3 (en) 2013-03-21
JP2014521089A (ja) 2014-08-25
AU2012282825A1 (en) 2014-01-16
EP2732289A2 (en) 2014-05-21
EP2732286A1 (en) 2014-05-21
US20140120037A1 (en) 2014-05-01
EP2732289B1 (en) 2018-04-11
MX2014000480A (es) 2014-06-23
CN103782171A (zh) 2014-05-07
KR20140072019A (ko) 2014-06-12
DK2732289T3 (en) 2018-05-22
BR112014000671A2 (pt) 2017-02-14
AU2012282825B2 (en) 2016-05-26
US20130052670A1 (en) 2013-02-28
CA2840976A1 (en) 2013-01-17
WO2013009703A8 (en) 2014-01-23
CN103782171B (zh) 2016-12-14
WO2013009667A1 (en) 2013-01-17
WO2013009703A2 (en) 2013-01-17
ES2666840T3 (es) 2018-05-08
EP2732286A4 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
JP2014521089A5 (cg-RX-API-DMAC10.html)
Barnum et al. Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro® 1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats
Wang et al. Ferulic acid ameliorates Alzheimer’s disease-like pathology and repairs cognitive decline by preventing capillary hypofunction in APP/PS1 mice
IL305904A (en) Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
US20160077111A1 (en) Detection of Misfolded Alpha Synuclein Protein
MX343327B (es) Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
Sylvestre et al. Untargeted metabolomic analysis of plasma from relapsing-remitting multiple sclerosis patients reveals changes in metabolites associated with structural changes in brain
KR20170062478A (ko) 우울증 치료약의 선택지를 예측하는 방법
BR112019024138A2 (pt) Método para determinar uma presença ou ausência em uma amostra de um primeiro agregado de proteínas mal enoveladas
WO2015027154A3 (en) Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
JP2013543581A5 (cg-RX-API-DMAC10.html)
Burks et al. One size may not fit all: anti-aging therapies and sarcopenia
Liu et al. Potential application of hydrogel to the diagnosis and treatment of multiple sclerosis
Nyawira Maranga et al. IL‐6 is upregulated in late‐stage disease in monkeys experimentally infected with Trypanosoma brucei rhodesiense
RU2449276C1 (ru) Способ дифференциальной клинико-лабораторной диагностики степени выраженности воспалительных изменений слизистой оболочки желудка и двенадцатиперстной кишки при хроническом гастродуодените у детей с контаминацией организма химическими веществами промышленного происхождения
Dalgėdienė et al. Activation of macrophages by oligomeric proteins of different size and origin
RU2013122853A (ru) Биомаркер для болезни альцгеймера или умеренного когнитивного расстройства
CN104689344B (zh) 应用于老年痴呆症的早期快速检测及其多模态成像的影像制剂
Nisa et al. Biomarker miRNA-146a sebagai deteksi dini yang efektif untuk Alzheimer
Wu et al. Blood-brain barrier breakdown in traumatic brain injury: current insights and future directions
Reed et al. 70. Cortisol Response to Psychosocial Stress and Working Memory Performance in Schizophrenia
Kuusi No Evidence of CNS Inflammatory Activity in Individuals with post-COVID-19 Condition Experiencing Neurological Symptoms: Insights from TSPO-PET Imaging
Díaz-Pérez Transcriptional Characterization of the Cellular Landscape in Vascular Dementia
Hicks et al. Traumatic Brain Injury Biomarkers, Simulations and Kinetics. Bioengineering 2022, 9, 612
Alverson Development and Characterization of a Closed-Head Mild Traumatic Brain Injury Model

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20170417